Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV: Bristol-Myers Squibb Company announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).
Monday, January 2, 2012
Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV
Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV: Bristol-Myers Squibb Company announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).
Sunday, January 1, 2012
Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia...
Alkermes plc (NASDAQ: ALKS) announced the initiation of a phase 3 clinical trial of ALKS 9070 (Aripiprazole) for the treatment of schizophrenia. ALKS 9070, a proprietary Alkermes molecule, is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole...
Ref : http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-corporateNewsArticle&ID=1640788&highlight=
Labels:
Aripiprazole,
schizophrenia. ALKS 9070
Friday, December 30, 2011
Lostartan can reduce cigarette smoke-induced lung injury
Researchers from Johns Hopkins University, BaltimoreLostartan, lead by have found that, Dr.Enid R. Neptune Losartan a drug used widely in the clinic (e.g., to treat high blood pressure),
reduced lung disease in mice caused by exposure to cigarette smoke.
Losartan blocks the protein angiotensin receptor type 1, and its effects
on cigarette smoke-induced lung injury were a result of the fact that
blocking angiotensin receptor type 1 leads to a decrease in levels of
the soluble molecule TGF-beta. The authors therefore suggest that other
TGF-beta-targeted therapeutics might also be viable candidates for the
treatment of chronic obstructive pulmonary disease, COPD....
Ref : http://www.jci.org/articles/view/46215?search[article_text]=&search[authors_text]=Enid+Neptune
Labels:
COPD,
losartan,
protein angiotensin receptor type 1
Thursday, December 29, 2011
MK 1775 shows promise against sarcomas..........
2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6- (4-(4-methyl- piperazin-1-yl)phenylamino)-1H-pyra -zolo [3,4-d]pyrimidin-3(2H)-one.
MK 1775 (see structure), a small, selective inhibitor molecule, has been found to be
active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Researchers found that MK1775 treatment induces apoptopic cell death in four sarcoma cell lines at clinically relevant doses.
To further prove that inhibition of Wee1 by MK1775 leads to mitotic
cell death in sarcomas cells, the researchers performed additional
studies, including studies on sarcomas related to mutations, such as
with the p53 gene.
They also showed that MK1775 was an active inhibitor of Wee1 regardless
of the p53 mutation status of the tumors in the cell lines tested.
"The cytotoxic effect of Wee1 inhibition on sarcoma cells appears to be independent of p53 mutation status following our testing sarcoma cell lines with different p53 mutations," he said. "All of them were highly sensitive to MK1775, suggesting that Wee1 inhibition may represent a novel approach in the treatment of sarcomas."
Researchers concluded that their laboratory tests on sarcoma cell lines
suggest that MK1775 is effective as a monotherapy even in the cell
lines that include p53 wild, p53 null and p53 mutant statuses.
Wednesday, December 28, 2011
Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint
In continuation of my update on gemcitabine
Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint: Oncolytics Biotech Inc. announced the interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active.
Labels:
(Gemzar),
advanced pancreatic cancer,
Gemcitabine,
REOLYSIN®
Tuesday, December 27, 2011
New Antibodies Treat Autoimmune Disease like Crohn's in Mice....
Synthetic drugs treat (below structure) Crohn's disease in mice.................
[zinc-binding motif (where X is any amino acid) in MMPs, a symmetrical tripodal tris-imidazol–zinc complex (Zn-tripod; ZnC36H59N11O8)]
New Antibodies Treat Autoimmune Disease in Mice
Ref : http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2582.html
[zinc-binding motif (where X is any amino acid) in MMPs, a symmetrical tripodal tris-imidazol–zinc complex (Zn-tripod; ZnC36H59N11O8)]
New Antibodies Treat Autoimmune Disease in Mice
Ref : http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2582.html
Labels:
Synthetic drugs Crohn's disease
Monday, December 26, 2011
Salk scientists develop new drug that improves memory and prevents brain damage in mice
A new drug candidate may be the first capable of halting the devastating mental decline of Alzheimer's disease, based on the findings by a research group of Salk's Cellular Neurobiology Laboratory.
When given to mice with Alzheimer's, the drug, known as J147 (see structure), improved memory and prevented brain damage caused by the disease. The new compound, developed by scientists at the Salk Institute for Biological Studies, could be tested for treatment of the disease in humans in the near future.
"J147 enhances memory in both normal and Alzheimer's mice and also protects the brain from the loss of synaptic connections," says David Schubert, the head of Salk's Cellular Neurobiology Laboratory, whose team developed the new drug. "No drugs on the market for Alzheimer's have both of these properties."
Although it is yet unknown whether the compound will prove safe and effective in humans, the Salk researchers' say their results suggest the drug may hold potential for treatment of people with Alzheimer's.
Sunday, December 25, 2011
Notch inhibitor appears to treat breast cancer....
In a novel therapeutic approach to treating breast cancer, Loyola University Medical Center researchers are reporting positive results from a clinical trial of a drug that targets tumor stem cells. A pilot study at Loyola found that an experimental drug known as a "notch inhibitor" appears to block this process by turning off key genes. Prior to surgery, the patients received one of two commonly used drugs, tamoxifen or letrozole. These drugs work by blocking estrogen stimulation of breast cancer cells. In addition to tamoxifen or letrozole, patients also received the experimental notch-inhibitor drug, MK-0752 (see structure).
"The notch inhibitor appears to be doing what it is intended to do," said Dr. Clodia Osipo....
There were minimal side effects from either the notch inhibitor or the estrogen-blocking drugs. One patient experienced puffy eyes and coughing and four patients experienced facial acne. No patients experienced diarrhea or surgical complications.
Saturday, December 24, 2011
Zoledronic Acid Shows Long-Term Benefit in Survivorship for Premenopausal ER-Positive Breast Cancer
In continuation of my update on Zoledronic acid....
Zoledronic Acid Shows Long-Term Benefit in Survivorship for Premenopausal ER-Positive Breast Cancer
Zoledronic Acid Shows Long-Term Benefit in Survivorship for Premenopausal ER-Positive Breast Cancer
Labels:
breast cancer,
Drug Discovery,
postmenopausal,
Zoledronic acid
Thursday, December 22, 2011
Scientists identify why African naked mole-rat feels no pain when exposed to acid
In continuation of my update naked mole-rat
Scientists identify why African naked mole-rat feels no pain when exposed to acid: British researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have found out why the African naked mole-rat (Heterocephalus glaber), one of the world's most unusual mammals, feels no pain when exposed to acid.
Ref : http://www.mdc-berlin.de/en/news/2011/20111220-mdc_researchers__ion_channel_makes_african1/index.html
Labels:
Drug Discovery,
med-chemist,
naked mole-rate
Tuesday, December 20, 2011
Drug Duo of Ixabepilone and sunitinib Kills Chemotherapy-resistant Ovarian Cancer Cells......
In continuation of Sunitinib...
The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida. Research suggests that this combination (ixabepilone and sunitinib), might offer a much needed treatment option for women with advanced ovarian cancer. When caught at late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it. The finding also highlights the importance of the role of a molecule, RhoB, that the researchers say is activated by the drug duo. Neither drug is approved for use in ovarian cancer. Ixabepilone is a chemotherapy drug that, like other taxane drugs, targets the microtubules and stops dividing cells from forming a spindle. It has been approved for use in metastatic breast cancer. Sunitinib, approved for use in kidney cancer, belongs to a class of tyrosine kinase inhibitors that stops growth signals from reaching inside cancer cells.
Sunday, December 18, 2011
Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases from Breast Cancer
In continuation of my update on Paclitaxel and drug discovery....
Geron Corporation, announced the initiation of GRABM-B (GRN1005 Against Brain Metastases - Breast
Cancer), a Phase 2 clinical trial to evaluate GRN1005 in patients with
brain metastases arising from breast cancer. GRN1005 is the company's
lead LRP-directed peptide-drug conjugate (LRP-directed PDC) that
consists of the cytotoxic drug, paclitaxel, linked to a peptide
(Angiopep-2) that targets the LRP receptor to cross the blood-brain
barrier (BBB) and to target tumors in the brain.
The purpose of the Phase
2 study is to assess the efficacy, safety and tolerability of GRN1005
in patients with brain metastases from breast cancer. The trial is
designed to include 100 patients with HER2 positive or HER2 negative
metastatic breast cancer (MBC) disease, who will be assessed in two
separate cohorts of 50 patients each.....
Ref : http://www.geron.com/media/pressview.aspx?id=1287
Saturday, December 17, 2011
Drug combination highly effective for newly diagnosed myeloma patients......
A three-drug combination treatment for the blood cancer multiple myeloma
compares favorably to the best established therapy for newly diagnosed
patients, according to a multi-center study led by Andrzej Jakubowiak,
MD, PhD, professor of medicine and director of the multiple myeloma
program at the University of Chicago Medical Center.
The combination includes an
investigational medicine called carfilzomib
combined with two standard medications: lenalidomide, an analogue of
thalidomide, and low-dose dexamethasone, an anti-inflammatory with
anti-cancer properties.
"This combination appears to deliver everything we expected and more," said Jakubowiak, who came to the University of Chicago this fall from the University of Michigan. "We have seen excellent efficacy — the best reported to date — without the neurotoxicity that has been problematic with other drug combinations."
Ref : http://www.uchospitals.edu/news/2011/20111206-myeloma.html
Friday, December 16, 2011
Synta's ganetespib shows potent in vitro and in vivo activity against multiple breast cancer types
Synta researchers have reported that, Ganetespib (structure) shows potent in vitro and in vivo activity against multiple types of breast cancer including HER2-positive, ER/PR positive, triple-negative, and inflammatory breast cancer.
"These results demonstrating that ganetespib potently
inhibits key signaling pathways involved in the growth and proliferation
of multiple forms of breast cancer are encouraging, and supportive of
the results presented earlier at this meeting showing single-agent,
anti-tumor activity in patients with breast cancer
who have progressed on or failed to respond to multiple prior
therapies," said Vojo Vukovic, M.D., Ph.D., Chief Medical Officer,
Synta.
Researchers conclude that, the combined preclinical and clinical results create a
strong rationale for advancing ganetespib development in both
HER2-positive and triple-negative breast cancer.
More : http://phoenix.corporate-ir.net/phoenix.zhtml?c=147988&p=irol-newsArticle&ID=1638540&highlight=
Subscribe to:
Posts (Atom)